Lidocaine hydrochloride CAS No:73-78-9
Lidocaine hydrochloride CAS No:73-78-9
Lidocaine hydrochloride, CAS 73-78-9 ,Local anesthesia,Lidocaine hydrochloride CAS No:73-78-9
Product Name: Lidocaine hydrochloride
Product Purity: ≥ 99.0%
CAS No ：73-78-9
Send Inquiry
Description
Lidocaine Hydrochloride Powder (USP/EP)
Premium Local Anesthetic API Manufacturer | Bulk Lidocaine HCl CAS 73-78-9 Supplier
Handling & Storage:
Highly soluble in water and ethanol. Store in a cool, dry, and well-ventilated pharmaceutical warehouse. Keep the container tightly sealed to prevent moisture absorption (hygroscopic nature). Optimal shelf life is 24 months under standard storage conditions.
Highly soluble in water and ethanol. Store in a cool, dry, and well-ventilated pharmaceutical warehouse. Keep the container tightly sealed to prevent moisture absorption (hygroscopic nature). Optimal shelf life is 24 months under standard storage conditions.
Product Introduction & Chemical Description
Lidocaine Hydrochloride (CAS 73-78-9), produced and supplied by Shaanxi Sunrise Pharmaceutical Co., Ltd., is an elite-grade, amide-type local anesthetic and Class Ib antiarrhythmic active pharmaceutical ingredient (API). Synthesized via our state-of-the-art, GMP-compliant catalytic process, our Lidocaine HCl powder features an exceptionally clean impurity profile, ensuring high-efficacy performance for pharmaceutical developers worldwide.
To satisfy various clinical delivery systems, we strictly monitor our crystallisation parameters to control particle size and polymorphic stability. This raw material is ideal for compounding into high-end local anesthetics, including subcutaneous injections, topical gels, dental formulations, and transdermal patches.
| CAS Number | 73-78-9 (Monohydrate) | 6108-05-0 |
| Chemical Name | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride monohydrate |
| Molecular Formula | C14H22N2O · HCl · H2O |
| Molecular Weight | 288.81 g/mol (Monohydrate) | 270.80 g/mol (Anhydrous) |
| Assay (Dried Basis) | 99.0% - 101.0% (Conforms to USP/EP/BP) |
| Appearance | White, crystalline, odorless powder |
| Melting Point | 75℃ - 79℃ |
| Solubility | Very soluble in water, freely soluble in ethanol (96%) |
| Standard Pack | 1 kg/bag (vacuum-sealed); 25 kg/cardboard drum |
Shaanxi Sunrise Supply Chain Advantages
Strict Pharmacopoeial Conformance
Our Lidocaine HCl API consistently maintains an assay purity ≥ 99.5%. It fully complies with USP43, EP11, BP, and CP standards. Heavy metals are strictly restricted under 10 ppm, with total related substances controlled below 0.5% to ensure maximum clinical safety.
Massive scale Industrial Production
Operating a standardized 100,000-class cleanroom facility, we boast an annual output exceeding 300 metric tons. This extensive production capability guarantees a stable, highly scalable supply chain for global generic drug formulators and medical device manufacturers.
Advanced Regulatory Support Package
We facilitate rapid market entry for our B2B partners by providing comprehensive technical dossiers. This includes batch-specific COA, MSDS, DMF support documents, and full factory GMP certification to accelerate your local regulatory approvals.
Mechanism of Action & Clinical Applications
Lidocaine Hydrochloride provides double-action therapeutic efficacy through targeted neural and cardiac receptor pathways:
Voltage-Gated Sodium Channel Blockade: Lidocaine HCl binds to the intracellular portion of sodium channels on neuronal membranes. By blocking the sodium ion influx, it inhibits the initiation and conduction of action potentials, delivering rapid local anesthesia.
Class Ib Cardiac Antiarrhythmic Action: Within myocardial tissues, Lidocaine shortens the action potential duration and effective refractory period in Purkinje fibers, suppressing ventricular automaticity and stabilizing cardiac rhythms.
Versatile Formulation Compatibility: Thanks to its outstanding water solubility and thermodynamic stability, it is highly compatible with epinephrine, buffer systems, and gel polymers.
Typical Certificate of Analysis (COA)
| Test Item | Specification (USP/EP Standards) | Actual Batch Result | Analytical Method |
|---|---|---|---|
| Appearance | White crystalline powder | Conforms | Visual Inspection |
| Identification | Matches Infrared Absorption (IR) Reference | Conforms | USP<197k>/ EP< |
| Assay (HPLC, Dried Basis) | 99.0% - 101.0% | 99.68% | Liquid Chromatography |
| pH (1% Aqueous Solution) | 4.0 - 5.5 | 4.75 | Potentiometric USP<791> |
| Water Content (Monohydrate) | 5.0% - 7.0% | 5.82% | Karl Fischer USP<921> |
| Residue on Ignition | ≤ 0.1% | 0.03% | Gravimetric USP<281> |
| Bacterial Endotoxins | ≤ 0.10 EU/mg (For Injection preparation) | 0.05 EU/mg | LAL Test USP<85> |
| Total Impurities | ≤ 0.5% | 0.12% | HPLC Area Normalization |
⚠ Safety Warning & Regulatory Declaration
Important Regulatory Notice: The anhydrous form of Lidocaine HCl (MW 270.80) is highly unstable and prone to degradation; our standard product is the stable Monohydrate crystalline form (MW 288.81), which serves as the global gold standard for clinical preparations. This product is a high-potency active pharmaceutical ingredient (API) intended exclusively for pharmaceutical manufacturing, laboratory research, and industrial formulation development. Shaanxi Sunrise Pharmaceutical Co., Ltd. does not sell raw chemical materials for direct personal consumption.